Skip to main content
TipRanks
Go Ultimate75% OFF

RaQualia Pharma Inc. (4579) AI Stock Analysis

1 Followers
JP:4579

RaQualia Pharma Inc.

(TSE/TYO:4579)

Select Model
Rating:61Neutral
Price Target:JPY 779.00â–²(5.27% Upside)
Action:reiterated
Date:11/17/26

RaQualia earns a moderately above-average score. The strongest support comes from technicals: the shares trade above all key moving averages with positive MACD, signalling a well-established uptrend, though short-term indicators are becoming stretched. Fundamentals are improving but middling — revenue has more than doubled off the 2023 low, margins are exceptionally high, the balance sheet is conservatively equity-funded with falling leverage, and cash flow has turned positive. However, the business remains dependent on lumpy milestone and licensing income, producing volatile margins, swinging cash flow and a modest ~4.6% return on equity. Valuation is the principal drag: a 44x P/E with no dividend leaves little margin for error if the next milestone cycle disappoints.

Positive Factors
Revenue and Profitability RecoveryThe sharp TTM revenue increase and return to operating and net profitability indicate meaningful commercial progress. If supported by continued product, licensing, or development activity, this improved earnings base can strengthen internal funding capacity and support investment in the pipeline over the next several quarters.
Negative Factors
Volatile Earnings HistoryThe shift from strong profits to losses and then back to profitability demonstrates that earnings have not followed a stable recurring pattern. Such volatility makes future results harder to forecast and increases reliance on the timing and success of milestones, licensing activity, or other non-recurring contributions.

RaQualia Pharma Inc. (4579) vs. iShares MSCI Japan ETF (EWJ)

-50%-25%0%25%50%75%100%125%JP:4579+7.40%EWJ+6.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 19.26B
Dividend Yield
―
Average Volume (3M)
200.50K
Price to Earnings (P/E)
44.4
Beta (1Y)
0.88
Revenue Growth
31.84%
EPS Growth
―
Country
Japan
Employees
85
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

RaQualia Pharma Inc. Business Overview & Revenue Model

Company Description

RaQualia Pharma Inc., established in 2008 and based in Nagoya, Japan, is a pharmaceutical company dedicated to the global research and development of innovative drug compounds. Its human therapeutic pipeline features several key candidates. Tegopraza...

RaQualia Pharma Inc. Financial Statement Overview

Summary

RaQualia is in a clear recovery phase. Revenue has nearly doubled from the 2023 trough (¥1.90bn) to ¥4.02bn on a TTM basis, gross margin is outstanding at ~80%, and profitability has returned with ¥590m operating profit and ¥349m net income after losses in 2023 and 2024. The balance sheet is the strongest pillar (Score 68): equity of ¥7.79bn funds ~73% of assets and debt-to-equity has fallen to 0.33 from 0.62. Cash flow has also swung positive (¥746m operating, ¥718m free cash flow) with minimal capex and free cash flow covering ~96% of net income. Offsetting this, earnings and cash generation remain lumpy and milestone-driven — operating cash flow has flipped between large positives and negatives over four years — return on equity is thin at ~4.6%, and leverage is far above the company's historically near-debt-free profile.

Income Statement

57Neutral

Balance Sheet

68Positive

Cash Flow

55Neutral
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue4.02B3.98B3.11B1.90B2.92B2.78B
Gross Profit3.23B3.27B2.48B1.66B2.69B2.46B
EBITDA1.06B985.17M188.27M-111.80M1.00B1.02B
Net Income348.52M273.12M-495.03M-323.66M723.39M755.79M
Balance Sheet
Total Assets10.70B10.51B9.66B6.93B6.26B5.23B
Cash, Cash Equivalents and Short-Term Investments4.81B3.24B3.34B3.76B3.93B2.66B
Total Debt2.53B2.90B3.45B432.02M222.34M39.07M
Total Liabilities2.91B3.62B4.08B809.83M760.67M446.19M
Stockholders Equity7.79B6.90B5.57B6.12B5.50B4.79B
Cash Flow
Free Cash Flow717.72M-423.98M84.24M-940.80M1.45B260.61M
Operating Cash Flow746.39M-356.63M180.94M-718.60M1.48B366.03M
Investing Cash Flow-298.84M124.32M-3.67B-135.37M-47.65M-279.25M
Financing Cash Flow803.03M380.26M2.98B793.45M-29.56M-16.44M

RaQualia Pharma Inc. Technical Analysis

Technical Analysis SentimentPositive
Last Price740.00

Price Trends

50DMA620.96Positive
100DMA562.29Positive
200DMA672.09Positive

Market Momentum

MACD32.44Negative
RSI64.40Neutral
STOCH83.71Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4579, the sentiment is Positive. The current price of 740.00 is above the 20-day moving average (MA) of 657.95, above the 50-day MA of 620.96, and above the 200-day MA of 672.09, indicating a bullish trend. The MACD of 32.44 indicates Negative momentum. The RSI at 64.40 is Neutral, neither overbought nor oversold. The STOCH value of 83.71 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4579.

RaQualia Pharma Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4579 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4565JP:456563NeutralJPY 154.11B-26.75-8.51%―23.72%12.48%
JP:4579JP:457961NeutralJPY 18.95B44.36――31.84%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4588JP:458851NeutralJPY 208.84B-125.84――1748.97%35.11%
JP:4587JP:458748NeutralJPY 144.11B-47.20-5.85%―14.25%50.07%
JP:4563JP:456342NeutralJPY 10.31B-1.77-558.92%―19.67%84.06%
JP:4571JP:457141NeutralJPY 6.37B-4.14-39.57%―48.92%-46.91%

* Healthcare Sector Average

Performance Comparison

0%200%400%600%JP:4579JP:4563JP:4587JP:4565JP:4571JP:4588Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4579 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4579RaQualia Pharma Inc.740.0051.007.40%
JP:4563AnGes 24.00-50.00-67.57%
JP:4587Peptidream 1060.00-566.00-34.81%
JP:4565Sosei Group Corporation1600.00738.0085.61%
JP:4571NanoCarrier Co., Ltd.65.00-79.00-54.86%
JP:4588Oncolys BioPharma, Inc.6940.005975.00619.17%

RaQualia Pharma Inc. Corporate Events

RaQualia Pharma Reports Nine-Month Results Through September 2026

Nov 13, 2026

RaQualia Pharma Inc. reported consolidated net sales of ¥2.35 billion for the nine months ended September 30, 2026, up 1.7% from a year earlier. Operating loss narrowed to ¥238 million from ¥344 million, ordinary loss narrowed to ¥261 million from ¥4...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026